Obermatt

T Man Pharmaceutical

SET:TMAN · THC209010006
PharmaceuticalsSmall

360

91
Profit price11
Owner Earnings Yield83
Dividend Yield81
Price/Sales61
EV / Gross Profit38
Price/Book52
Return on Capital96
Cash Return on Capital95
Return on Equity96
EBIT Margin98
Gross Profitability69
Cash Conversion19
Accruals37
Owner Earnings Margin100
Sales growth83
Profit Growth19
Long-Term EPS Growth54
Owner Earnings Growth59
Reinvestment96
Price momentum57
Debt load45
Refinancing72
Debt Payback78
Liquidity68
Analyst ratings100
Opinion Changes50
Price Target Upside30
Market mood1
Value Creation18/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

T Man Pharmaceutical generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountryThailand
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeSET
Founded2023
Employees30
ISINTHC209010006
Last UpdateApr 2, 2026

Description

Analysis

Quality compounder

T.Man Pharmaceutical Public Company Limited earns the quality_compounder label: good underlying economics priced fairly, with no obvious bargain or excess. Worth noting: the cash the business generates has lagged behind what the income statement shows.

On valuation, the picture is attractive. The owner-earnings multiple stands at 10.1×; owner earnings: the cash an owner could take out each year.

Growth is moderate; the safety picture is sturdy. The company scores 18/20 on our value-creation score: strong value creator.

Flags to be aware of: Some accounting patterns deserve a closer look. Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
67
2026

All-time high

75

Mar 2026

All-time low

67

Jun 2026

Average rank

71

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
61
Price/Earnings
69
Price/Book
52
Dividend Yield
81
Value (overall)
82

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare T Man Pharmaceutical with its peers
KCG Corporation
SET:KCG
100
CountryThailand
IndustryFood Products
SizeSmall
Full Stock Analysis →
Fine Organic Industries
NSI:FINEORG
54
CountryIndia
IndustryChemicals
SizeMedium
Full Stock Analysis →
Medeze
SET:MEDEZE
85
CountryThailand
IndustryHealth Care Providers & Services
SizeSmall
Full Stock Analysis →
SCG Décor
SET:SCGD
95
CountryThailand
IndustryBuilding Products
SizeSmall
Full Stock Analysis →
Bangkok Lab and Cosmetic
SET:BLC
55
CountryThailand
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
K Wave Media
NMQ:KWM
13
CountryCayman Islands
IndustryEntertainment
SizeX-Small
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →